Trial Profile
An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs AZD 3409 (Primary)
- Indications Hepatitis D
- Focus Proof of concept; Therapeutic Use
- Sponsors Eiger BioPharmaceuticals
- 04 Aug 2016 Status changed from recruiting to discontinued.
- 17 Mar 2011 New trial record